Australia's most trusted
source of pharma news
Friday, 14 February 2025
Posted 29 July 2024 AM
New research has found that GSK's shingles vaccine Shingrix is linked to a larger reduction in the risk of dementia than MSD's vaccine, Zostavax.
When Zostavax was launched in 2006 several studies suggested that the risk of dementia might be lower in people who had received the vaccine, although the results were inconclusive. With the vaccine largely replaced by Shingrix, there were concerns that results from prior studies were no longer relevant.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.